检索规则说明:AND代表“并且”;OR代表“或者”;NOT代表“不包含”;(注意必须大写,运算符两边需空一格)
检 索 范 例 :范例一: (K=图书馆学 OR K=情报学) AND A=范并思 范例二:J=计算机应用与软件 AND (U=C++ OR U=Basic) NOT M=Visual
作 者:NADEZHDA PALKINA EKATERINA SERGEEVA TATIANA RUKSHA
机构地区:[1]Krasnoyarsk State Medical University,Krasnoyarsk,660022,Russian Federation
出 处:《Oncology Research》2021年第6期393-400,共8页肿瘤学研究(英文)
基 金:supported by Russian Science Foundation(No.19-15-00110,https://rscf.ru/project/19-15-00110/).
摘 要:Melanoma is one of the most aggressive types of malignant tumors,commonly affecting young individuals.The treatment of metastatic tumors remains obscure due to the resistance of tumor cells to drugs mediated by various mechanisms.The acquisition of a resistant phenotype is associated with both genetic and epigenetic alterations in cancer cells.Therefore,the current study aimed to investigate whether microRNA(miR)-204-5p could promote alterations in the cell cycle and apoptosis of dacarbazine(DTIC)-treated melanoma cells.Quantitative real time PCR showed that transfection of DTIC-treated SK-MEL-2 melanoma cells with miR-204-5p mimics significantly upregulated miR-204-5p.However,flow cytometric analysis revealed that the proportion of cells in different phases of the cell cycle remained unchanged.Additionally,the proportion of early apoptotic cells was notably enhanced following cell treatment with DTIC,accompanied by a profound increase in Ki-67 negative cells,as verified by an immunofluorescence assay.Furthermore,miR-204-5p overexpression reduced the percentage of early apoptotic DTIC-treated melanoma cells.The proportion of Ki-67 negative cells was only increased by 3%.Overall,the results of the current study indicated that miR-204-5p overexpression could mostly attenuate cell apoptosis in DTIC-treated cells rather than promote their transition from the G0 phase of the cell cycle in response to chemotherapeutic agent-induced stress.
关 键 词:Cell cycle SENESCENCE KI-67 MICRORNA
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在链接到云南高校图书馆文献保障联盟下载...
云南高校图书馆联盟文献共享服务平台 版权所有©
您的IP:216.73.216.13